Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) just unveiled an announcement.
Hikma Pharmaceuticals has granted conditional share awards to senior executives under its 2023 Long Term Incentive Plan and Deferred Bonus Plan, using a reference share price of £12.71. Awards cover key leaders including the CEO and regional deputies, and are subject to continued employment, performance conditions, and malus and clawback provisions, with vesting periods ranging from two to three years plus additional holding requirements.
In response to recent share price volatility and a decline in its stock since last year’s grant, the Remuneration Committee has cut performance share plan awards for managers by 16.2%, equivalent to half the share price fall. The committee also reserved the right to adjust vesting outcomes to avoid windfall gains, signalling a tighter alignment of executive pay with shareholder value and market performance amid a weaker share price backdrop.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a UK-based multinational pharmaceutical company listed in London and on Nasdaq Dubai. It focuses on manufacturing and supplying generic and branded medicines, with a significant presence across MENA, North America and Europe, serving hospital and retail markets with injectable, oral and other pharmaceutical products.
Average Trading Volume: 1,379,074
Technical Sentiment Signal: Sell
Current Market Cap: £2.84B
Learn more about HIK stock on TipRanks’ Stock Analysis page.